VivoSeq
Nephrology

End Stage Renal Disease (ESRD)

0

Pipeline Programs↗

2

Active Trials↗

11

Companies Involved↗

End Stage Renal Disease (ESRD) is an early-stage landscape with 0 programs across 11 companies. The most active players are Amgen, Merck & Co., Keryx Biopharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalK

Keryx Biopharmaceuticals

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalP

Pinta Biotherapeutics

0 programs

PreclinicalIonis Pharmaceuticals logo

Ionis Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed19 · 83%
Unknown status1 · 4%
Withdrawn1 · 4%
Not yet recruiting1 · 4%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Active, not recruiting·HHumacyte, Inc.·Phase 3·NCT05908084·121 enrolled
Comparative Pilot Trial of Oral Sodium Bicarbonate Versus Increased Dialysate Bicarbonate in Chronic Hemodialysis Patients With Metabolic Acidosis
Not yet recruiting·UUniversity of Sfax·Preclinical·NCT07688434·37 enrolled
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
Completed·RRockwell Medical Technologies, Inc.·Phase 2·NCT00548249·131 enrolled
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
Completed·Amgen logoAmgen·Phase 2·NCT00113945·360 enrolled
A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT03000673·32 enrolled
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
Completed·PPinta Biotherapeutics·Phase 1/2·NCT01958970·51 enrolled
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
Completed·Amgen logoAmgen·Phase 1·NCT02054572·6 enrolled
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 2·NCT03358030·213 enrolled
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
Completed·DDynavax Technologies Corporation·Phase 1·NCT03934736·119 enrolled
Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
Completed·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 4·NCT04689737·8 enrolled
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT06814132·24 enrolled
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT05335005·12 enrolled
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00240331·2,776 enrolled
A Research Study for Patients With End-Stage Renal Disease (ESRD)
Completed·Amgen logoAmgen·Phase 4·NCT00110890·552 enrolled
A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
Completed·EEpizon Pharma, Inc.·Phase 2·NCT05285787·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)